Clinical Trial Update: NALIRIFOX as Induction Therapy in LAPC [Phase 2]

View source ↗

Summary

Phase 2 trial update for NALIRIFOX induction therapy in locally advanced pancreatic cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Liposomal irinotecan (liposomal irinotecan)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING